VUB-VIB Bio Incubator Brussels © Thierry Geenen

VUB and VIB launch new Bio Incubator Brussels on VUB campus

Catalyst for collaboration and biotechnological innovation

Brussels & Ghent, Belgium, 5 December 2024 - The Vrije Universiteit Brussel (VUB) and VIB have joined forces to launch the brand-new Bio Incubator Brussels (BIB) on the green VUB Main Campus in Etterbeek. This innovative hub brings together science, technology, and entrepreneurship to transform groundbreaking biotechnological advancements into new companies. Start-ups in the fields of biotechnology, pharmaceuticals, and health technology can now utilize this facility, which offers ready-to-use lab and office spaces. The VIB Nanobody Core Facility was the first to move in.

The bio-incubator was established on the initiative of and with financial support from the VIB-VUB Center for Structural Biology. This research center, led by Jan Steyaert and Han Remaut, has a strong track record of successful biotech spin-offs, such as Ablynx, Biotalys, and Confo Therapeutics.

“With this new bio-incubator, we aim to facilitate the creation of start-ups in their early stages and strengthen the link between our lab and our spin-offs,” says Prof. Jan Steyaert, Scientific Director of the VIB-VUB Center for Structural Biology.

Bridge between innovation and collaboration

The Bio Incubator Brussels offers a stimulating ecosystem for innovation and scientific collaboration. The spaces are equipped with state-of-the-art lab furniture and include shared lab facilities, modern office spaces, and a wide range of support services. These services include mentorship, networking opportunities, and direct access to academic talent and industrial partners closely associated with the university and institute.

Jan Danckaert, rector of the VUB, highlights the incubator’s importance: “The establishment of the Bio Incubator Brussels reinforces VUB’s role in translating scientific research into societal and economic applications. It is a critical platform that will shape an ecosystem for companies and scientists to collaborate on solutions and applications in life sciences and health technology that will make a difference in the near future.”

VIB Nanobody Core Facility takes the lead

The first organization to set up in the bio-incubator is the VIB Nanobody Core Facility. This facility specializes in developing nanobodies, unique antibodies used in the biomedical and pharmaceutical sectors to create new treatments.

Dr. Gholamreza Hassanzadeh Ghassabeh, head of the Nanobody Core Facility, expressed his enthusiasm: “Bio Incubator Brussels provides us with the opportunity to further develop our research on nanobodies in a stimulating environment, surrounded by experts and companies who can support our innovation process. This is a fantastic chance to link scientific progress with commercial applications that can make a real impact on healthcare.”

For more information and to arrange a visit, go to https://www.vubtechtransfer.be/bio-incubator-brussels-bib.

Contacts

David Moreels

​Incubator Manager VUB 

​0488 66 67 95 

david.moreels@vub.be 

 

Jan Steyaert

​Scientific Director VIB-VUB Center for Structural Biology

​0495 27 02 48 

jan.steyaert@vub.be

www.steyaertlab.be ​ ​ 

 

Share

Latest stories

Website preview
New tool makes gene regulation easier to study—and tweak
Leuven, 2 April 2026 - Understanding how genes are switched on and off in specific cell types remains one of biology’s central challenges. While AI has made major progress in decoding the regulatory logic of DNA, applying these approaches across datasets, tissues, and species has remained difficult. In a new Nature Methods paper, a research team led by Prof. Stein Aerts (VIB & KU Leuven) presents CREsted, a software package that enables both the analysis and design of gene regulatory elements in a systematic and scalable way.
press.vib.be
Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be